Scientists at ORNL have developed 3D-printed collimator techniques that can be used to custom design collimators that better filter out noise during different types of neutron scattering experiments
How do you get water to float in midair? With a WAND2, of course. But it’s hardly magic. In fact, it’s a scientific device used by scientists to study matter.
The founder of a startup company who is working with ORNL has won an Environmental Protection Agency Green Chemistry Challenge Award for a unique air pollution control technology.
In fiscal year 2023 — Oct. 1–Sept. 30, 2023 — Oak Ridge National Laboratory was awarded more than $8 million in technology maturation funding through the Department of Energy’s Technology Commercialization Fund, or TCF.
Dean Pierce of ORNL and a research team led by ORNL’s Alex Plotkowski were honored by DOE’s Vehicle Technologies Office for development of novel high-performance alloys that can withstand extreme environments.
ORNL will team up with six of eight companies that are advancing designs and research and development for fusion power plants with the mission to achieve a pilot-scale demonstration of fusion within a decade.
Researchers at ORNL are tackling a global water challenge with a unique material designed to target not one, but two toxic, heavy metal pollutants for simultaneous removal.
ORNL researchers used the nation’s fastest supercomputer to map the molecular vibrations of an important but little-studied uranium compound produced during the nuclear fuel cycle for results that could lead to a cleaner, safer world.
A team led by the U.S. Department of Energy’s Oak Ridge National Laboratory demonstrated the viability of a “quantum entanglement witness” capable of proving the presence of entanglement between magnetic particles, or spins, in a quantum material.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.